Company profile
Draupnir Bio company profile
Draupnir Bio intends to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company is developing a platform for exploring the glycome to develop novel therapeutics, based on array technology, protein chemistry, and advanced carbohydrate chemistry. The company is able to synthesize, screen, and select highly potent and specific heparan sulfate glycomimetic drug candidates in cardiovascular, inflammatory, and infectious diseases.
Business identity
- Website
- http://www.draupnir.bio/
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00011-00050 employees
- Revenue range
- $10M+
- Founded
- 2017-01-01
Headquarters
- Headquarters
- Karup, Central Jutland, Denmark
- Postal code
- 8240
- Country code
- DK
- Continent
- Europe